Form 6-K ANFIELD ENERGY INC. For: Aug 14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.20549

 

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2026

 

Commission File Number: 001-42808

 

 

Anfield Energy Inc.

(Translation of registrant’s name into English)

 

2005-4390 Grange Street, Burnaby, British Columbia, Canada, V5H 1P6

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☐ Form 40-F ☒

 

 

 

INCORPORATION BY REFERENCE

 

Exhibits 99.1 and 99.2 of this Form 6-K of Anfield Energy Inc. (the “Company”) are hereby incorporated by reference into the Registration Statement on Form F-10, as amended (File No. 333-291078), of the Company, as amended or supplemented.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Anfield Energy Inc.
	(Registrant)
Date: August 14, 2026
	By:	/s/ Corey Dias
		Corey Dias
		Chief Executive Officer

 

 

EXHIBIT INDEX

 

Exhibit		Description
99.1		Unaudited Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2026 and 2025
99.2		Management’s Discussion and Analysis for the three and six months ended June 30, 2026 and 2025
99.3		CEO Certification
99.4		CFO Certification

 

 

ATTACHMENTS / EXHIBITS

EX-99.1

EX-99.2

EX-99.3

EX-99.4

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Labor and Employment Firm Zakay Law Group APLC Files A Class Action Lawsuit Against Abode Services Alleging Failure to Pay All Wages Due
• Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque P
• Citadel Income Fund Announces Annual Redemption of up to 262,689 Units